The antiandrogenic effects of seven phthalates, di(2-ethylhexyl)
phthalate (
DEHP),
dibutyl phthalate (DBP),
butyl benzyl phthalate (
BBP), di-isononyl
phthalate (DINP),
di-isodecyl phthalate (DIDP), di-n-heptyl
phthalate (
DnHP), and mono-2-ethyhexyl
phthalate (
MEHP), were investigated by Hershberger assay in castrated male SD rats. An
androgen agonist,
testosterone (0.4 mg/kg/d), was administered for 10 consecutive days by subcutaneous (s.c.) injection as a positive control. Additionally, 20, 100, or 500 mg/kg
body weight (bw)/d of 6 phthalates (
DEHP, DBP,
BBP, DINP, DIDP, or
DnHP) or 10, 50, or 250 mg/kg bw/d of
MEHP, the primary metabolite of
DEHP, were also administered orally in combination with
testosterone (0.4 mg/kg/d, s.c.) for 10 consecutive days, respectively. In the
testosterone-treated groups, glans penis, seminal vesicles, ventral prostate, and levator ani/bulbocavernosus muscles (LABC) weights were found to be significantly increased. Ventral prostate weights were significantly decreased in animals treated with
DEHP or DBP at doses of 20 mg/kg bw/d or above, 500 mg/kg bw/d DIDP, and 250 mg/kg bw/d
MEHP. Seminal vesicles weights were also significantly decreased by
DEHP at > 100 mg/kg bw/d, DINP at > 20 mg/kg bw/d, DIDP at 500 mg/kg bw/d, or
MEHP at 50 or 250 mg/kg bw/d, respectively. In addition, LABC weights were decreased by
DEHP at 500 mg/kg bw/d, DINP at 500 mg/kg bw/d, and
MEHP at 50 or 100 mg/kg bw/d. These data suggest that some phthalates possess antiandrogenic activity, and that multiple cross-talk between
androgen,
estrogen, and
steroid hormone receptors occurs.